NewEdge Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

NewEdge Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100	Closed	-$420	–	3692
2023 Q1	$420	Buy	100 +99	+9,900%	+$514	﹤0.01%	3255
2022 Q4	$0	Buy	+1	New	+$5	﹤0.01%	4281

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

NewEdge Advisors's CTIC Position: Q2 2023 in Review

NewEdge Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 100 shares — an estimated $420 sold.

NewEdge Advisors first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $420 in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

NewEdge Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
NewEdge Advisors sold 100 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $420.
NewEdge Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
NewEdge Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $420 in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on NewEdge Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.